Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by JOKINEN, E. I.
Right arrow Articles by ARVILOMMI, H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by JOKINEN, E. I.
Right arrow Articles by ARVILOMMI, H. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1994 British Society for Rheumatology

research-article

PREDICTION OF SEVERE RHEUMATOID ARTHRITIS USING EPSTEIN-BARR VIRUS

E. I. JOKINEN*, T. T. MÖTTÖNEN{dagger}, P. J. HANNONEN{ddagger}, M. MÄKELħ and H. S. ARVILOMMI,

*The Department of Cell Biology, University of Jyväskylä
{ddagger}Central Hospital Jyväskylä
{dagger}University Central Hospital Turku
§Department of Virology, University of Turku
National Public Health Institute, Department in Turku Turku, Finland

Correspondence to: Correspondence to: H. S. Arvilommi, National Public Health Institute, Department in Turku, Box 57, SF-20521 Turku, Finland.

One of the immunological abnormalities in patients with RA is increased synthesis of immunoglobulins (Ig) in cultures of Epstein-Barr virus (EBV-) stimulated lymphocytes. We set out to investigate whether this feature, seen early in the disease, associated with later severe RA. We studied prospectively 45 patients with recent onset RA and, 41 healthy individuals. From 0–6 months after admission, blood lymphocytes were cultured in the presence of EBV for 4 weeks and Ig in the supernatants were assayed. To assess the severity of disease, clinical, laboratory and radiological evaluations were performed every 6 months for 2 yr. The association of increased Ig production with the severity of RA was then analysed. During the follow-up period, 30 of the original 45 patients developed erosive disease. At onset, these 30 patients did not differ from the 15 with non-erosive disease when assessed by several parameters reflecting rheumatoid activity. However, EBV-induced production of Ig was significantly higher in the erosive compared with the non-erosive group of patients (P<0.001). Using Ig synthesis, it was possible to identify a subgroup of 9–14 patients, depending on the isotype studied, who would later develop severe erosive disease (PVpos = 90–100%). These results show that high EBV-induced production of Ig early in RA associates with later severe disease, particularly with joint erosions. This feature identifies, with over 90% likelihood, the third of patients who will later develop most severe disease.

KEY WORDS: Rheumatoid arthritis, Epstein-Barr virus, Prediction of outcome


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
D. A. Yarilin, J. Valiando, and D. N. Posnett
A Mouse Herpesvirus Induces Relapse of Experimental Autoimmune Arthritis by Infection of the Inflammatory Target Tissue
J. Immunol., October 15, 2004; 173(8): 5238 - 5246.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
E. Toussirot, D. Wendling, P. Tiberghien, J. Luka, and J. Roudier
Decreased T cell precursor frequencies to Epstein-Barr virus glycoprotein gp110 in peripheral blood correlate with disease activity and severity in patients with rheumatoid arthritis
Ann Rheum Dis, July 1, 2000; 59(7): 533 - 538.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.